The occurrence of donor-derived AML is a rare event after allogeneic BMT, which on occasion can develop as a de novo secondary hematologic malignancy within a general susceptibility of secondary cancer after BMT. Furthermore, transmission of hematologic disturbances of donor origin has to be taken into consideration.
We report the case of a 69-year-old man who had a BMT from his HLA-B-Ag-mismatched sister for first chronic phase Ph-positive chronic myeloid leukemia (CML) in November 1991. He achieved complete cytogenetic remission until relapse occurred in July 1996. IFN-a treatment was initiated, but produced only a hematologic response with persisting positive BCR-ABL transcripts and a Ph-chromosome. The patient entered accelerated phase in July 2002. Imatinib was then added to the IFN-a and he was restored again to chronic phase in February 2003. He continued with imatinib alone because of thrombocytopenia and finally abandoned it in July 2006 owing to an overall BM toxicity and poor hematopoiesis. Molecular remission was achieved in October 2005 and donor lymphocyte infusions in escalating doses were administered to consolidate the molecular remission. In February 2007, a donor stem cell boost had to be given because of persistent plt and erythrocyte transfusion-dependent pancytopenia requiring G-CSF in the context of emerging molecular relapse. Before stem cell boost a mixed chimerism status and an increase of BCR-ABL transcript levels in the BM was documented. Stem cells were given after CD34 þ purification by ex vivo T-cell depletion to minimize the risk of acute GVHD. Additional immunosuppression was not given. The stem cell boost resulted in hematologic recovery with confirmed complete molecular remission in the peripheral blood. Signs of acute or chronic GVHD were not detectable. However, 6 months later the patient presented with fever and significant weight loss, decreased plts, detection of BCR-ABL expression in quantitative PCR analyses (0.24% b3a2 BCR-ABL/GAPDH expression) and the occurrence of myeloid blasts in the peripheral blood. On the assumption that this was blast crisis of CML, imatinib treatment was restarted, but although peripheral blasts increased to 80%, quantitative BCR-ABL expression diminished. Blood examination using XY-FISH revealed 98.8% initially and then 4 weeks later 100% female karyotype. BM histology suggested AML with 20% CD117 positive blasts. As shown in Figure 1 peripheral blood cytogenetic analysis showed an abnormal karyotype 45,XX,t(3;6)(q26;q23),À7 [6] , 45,XX,t(3;6)(q26;q23),À7,dup(21) (q11q22) [14] . FISH examination detected monosomy 7 in 95, three AML1 signals in 88 and an EVI1/3q26 rearrangement in 97 of 100 analyzed interphase nuclei corresponding to the chromosomal findings. To exclude an inadvertent transmission of a donor type malignancy the BM of the 70-year-old sister was examined, but no chromosomal aberration or morphological evidence of any hematological disorder could be identified. Comparison between recipient and donor BM by using genetic fingerprinting confirmed 100% concordance in 3 of 4 highly polymorphic genetic markers, which confirmed genetic identity with a P of error o1:10 6 . In summary, we found a clonal evolution of donorcell leukemia displacing the primary CML clone, which occurred during imatinib therapy subsequent to the administration of a T cell-depleted stem cell boost.
It is well known that hematological disorders can be transferred by hematopoietic stem cells 1, 2 and even a few cases of secondary hematological diseases in stem cell recipients have been described. 3, 4 On the other hand, development of AML has been observed during or after imatinib treatment for chronic phase CML 5 and other chromosomal aberrations, such as trisomy 8 or monosomy 7, are commonly reported to be involved. 6 Although the underlying mechanisms of donor-derived leukemogenesis are speculative and certainly multifactorial, the clonal conversion of intact hematopoietic progenitor cells in the absence of T-cell regulation, within an altered BM microenvironment, might be facilitated by signal transduction inhibition. As there is some evidence that imatinib inhibits CD8 þ and also regulatory T cells, 7 which are involved in tumor control, this might explain an increased mutagenic potential of BCR-ABL tyrosine kinase inhibitors under specific conditions. 
